This AIM stock is flying today but I’d rather buy this FTSE 100 stock yielding 8%

Harvey Jones says there’s still money to be made in bricks & mortar. Take this FTSE 100 (INDEXFTSE: MCX) stock for instance.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AIM-listed OnTheMarket (LSE: OTMP) is up more than 6% today despite publishing an operating loss of £14.5m in its final results, more than a third higher than 2018’s £10.8m.

Deadly duopoly

That hasn’t hurt the OnTheMarket share price, quite the reverse. Perhaps that’s because the loss is due to the estate agency-backed group’s plan to invest heavily in its business as it looks to wrestle power, revenues and eyeballs from the Rightmove and Zoopla duopoly.

The company’s administrative expenses almost tripled, from £9.7m to £27.8m, as it hired new marketing staff, while advertising expenditure jumped from £2.2m to £14.9m. That’s in line with its growth strategy, and management said the marketing spend was “more efficient than originally envisaged.”

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

On target

OnTheMarket boasted a solid cash balance of £15.7m on 31 January, up from £3.2m, helped by last summer’s fund raising and a “lower-than-planned cash burn.”

Group revenues climbed to £14.2m, although that’s a rise of just 4.4% over the year. The company has now signed listing agreements with more than 12,500 estate and letting agents. Of these, 5,500 were paying fees at the IPO in February 2018. The remaining 7,000 are on free or discounted rolling one-year deals with the option to pay at expiry. So far, 1,000 have done so. The average spend is £337 a month, but it remains to be seen whether its growth strategy will find long-term traction.

Traffic up

OnTheMarket stock is down 35% over the past year but site traffic is growing, with a record 25.4m visits in May, while also generating healthy leads for estate agent customers. The £70m company only listed in February last year and has a long way to go. Today’s results show promise, but it remains relatively high risk. Rupert Hargreaves would buy it, though.

I would rather play safe and buy one of the big FTSE 100 housebuilders such as Barratt Developments (LSE: BDEV) instead. This sector is also risky as Brexit drags interminably on and concerns grow over demand levels when the Help to Buy scheme is restricted to first-time buyers only from April 2021, a date that’s moving inexorably closer.

Investors in Barratt have shrugged off these worries with the stock recovering 26% in the last six months, although it has dipped lately as Brexit no-deal fears grow. Personally, I reckon you can only worry so much about political events such as Brexit. If you wait until that’s resolved, you wouldn’t buy a UK-focused companies for years.

Rock bottom rates

Help to Buy doesn’t worry me either. There’s a growing number of attractive mortgage deals at 90% and 95% that buyers can turn to when this scheme expires. Property remains in short supply and demand is voracious. Mortgage rates are at all-time lows and the chances of a base rate hike are now vanishingly thin, especially with the Fed looking to cut. All this should prop up the market.

Barratt is valued at a bargain 8.6 times forward earnings, roughly half the FTSE 100 average, and yields a forecast 8% with cover of 1.5. Earnings growth looks steady. People still need homes. Neil Woodford bought it, but don’t let that put you off.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

How a stock market crash could boost investors’ passive income by over 40%

Jon Smith explains how a continued fall in the stock market isn't always a bad thing, especially when it comes…

Read more »

Investing Articles

If an investor put £10k into Greggs shares one month ago, here’s what they’d have today

Greggs shares have had a tough year but Harvey Jones says they're notably cheaper as a result, while the dividend…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Phoenix share price jumps 7.5% on today’s results, but still yields a stunning 9.4%!

Harvey Jones put his faith in the Phoenix share price and this morning was rewarded with a 7.5% jump on…

Read more »

Investing Articles

What’s been going on with the Barclays share price?

The rising Barclays share price reflects confidence in management’s strategy to improve business performance and enhance shareholder returns.

Read more »

Investing Articles

Prediction: in 1 year, the IAG share price could reach as high as…

The IAG share price has almost doubled in the last 12 months, but can this momentum continue in 2025? Zaven…

Read more »

Investing Articles

Prediction: in 12 months, here’s where the Glencore share price could be…

The performance of Glencore’s share price has been lacklustre, to say the least. But could all that change over the…

Read more »

Investing Articles

See how much an investor needs in their ISA to earn a £499 monthly second income

Harvey Jones crunches the numbers to show how it's possible to build a long-term second income by investing in a…

Read more »

Investing Articles

I’m considering buying more of this struggling FTSE 100 stock

This FTSE 100 stock hasn't exactly set our writer's portfolio on fire during the time he's owned it. But Paul…

Read more »